A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, FIRST-IN-HUMAN, LOCAL TOLERABILITY AND DOSE ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF MULTIPLE-DOSE, TOPICAL ADMINISTRATION OF PF-07038124 TO HEALTHY PARTICIPANTS
Latest Information Update: 18 May 2020
At a glance
- Drugs PF 07038124 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; First in man
- Sponsors Pfizer
Most Recent Events
- 12 May 2020 Status changed from recruiting to completed.
- 15 Nov 2019 Status changed from not yet recruiting to recruiting.
- 30 Oct 2019 New trial record